Shopping Cart 0
Cart Subtotal
USD 0

Asia Pacific Human Insulin Market 2020-2026 by Product Type (Drugs, Delivery Devices), Application (Type 1 Diabetes, Type 2 Diabetes, Others), Distribution Channel, and Country: Trend Forecast and Growth Opportunity

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2480

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 3300

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 4100

Details

Asia Pacific human insulin market will grow by 9.74% annually over forecast years with a total addressable market cap of USD 66.02 billion for 2020-2026.

Highlighted with 37 tables and 56 figures, this 113-page report Asia Pacific Human Insulin Market 2020-2026 by Product Type (Drugs, Delivery Devices), Application (Type 1 Diabetes, Type 2 Diabetes, Others), Distribution Channel, and Country: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire Asia Pacific human insulin market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. In this report 2019 is the base year for market analysis, with estimates and forecast covering 2020-2026. (Please Note: The report will be updated before delivery to make sure that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

o Market Structure

o Growth Drivers

o Restraints and Challenges

o Emerging Product Trends & Market Opportunities

o Porter's Fiver Forces

The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view. The balanced (most likely) projection is used to quantify Asia Pacific human insulin market in every aspect of the classification from perspectives of Product Type, Application, Distribution Channel, and Country.

Based on product type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.

o Human Insulin Drugs

o Human Insulin Delivery Devices

Based on product, the Asia Pacific Human Insulin Drugs market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.

o Modern Human Insulin (further segmented into Long-acting, Rapid- acting, Premixed by type; further segmented into Lantus, Apidra, Levemir, NovoRapid/ NovoLog, Novomix, Humalog, Others by brand)

o Traditional Human Insulin (further segmented into Short-acting, Intermediate & Rapid-acting, Premixed by type; further segmented into Humulin, Insuman, Novolin/Actrapid/Insulatard by brand)

Based on product, the Asia Pacific Human Insulin Delivery Devices market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.

o Syringes

o Pens (further segmented into Disposable, Reusable, Pen needles)

o Pumps

o Others

Based on application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.

o Type 1 Diabetes

o Type 2 Diabetes

o Gestational Diabetes and Prediabetes

Based on distribution channel, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.

o Hospital Pharmacies

o Retail Pharmacies

o Online Pharmacies

Geographically, the following national/local markets are fully investigated:

o Japan

o China

o South Korea

o Australia

o India

o Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)

For each of the aforementioned countries, market analysis and revenue data are available for 2019-2026. The breakdown of major national markets by Product Type, Application, and Distribution Channel over the study years (2019-2026) is included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in Asia Pacific human insulin market are assayed quantitatively and qualitatively through GMD's Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players:

Astra Zeneca PLC

Biocon

Eli Lilly

Exir

Julphar

Novo Nordisk AS

Pfizer

Sanofi Aventis

Sedico

Wockhardt

(Please Note: The report will be updated before delivery to make sure that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

READ MORE

Table Of Content

Scope

1 Introduction 7

1.1 Industry Definition and Research Scope 7

1.1.1 Industry Definition 7

1.1.2 Research Scope 8

1.2 Research Methodology 10

1.2.1 Overview of Market Research Methodology 10

1.2.2 Market Assumption 11

1.2.3 Secondary Data 11

1.2.4 Primary Data 11

1.2.5 Data Filtration and Model Design 12

1.2.6 Market Size/Share Estimation 13

1.2.7 Research Limitations 14

1.3 Executive Summary 15

2 Market Overview and Dynamics 17

2.1 Market Size and Forecast 17

2.2 Major Growth Drivers 18

2.3 Market Restraints and Challenges 21

2.4 Emerging Opportunities and Market Trends 24

2.5 Porter's Fiver Forces Analysis 27

3 Segmentation of Asia-Pacific Market by Product Type 31

3.1 Market Overview by Product Type 31

3.2 Human Insulin Drugs 33

3.3 Human Insulin Delivery Devices 34

4 Segmentation of Asia-Pacific Human Insulin Drugs Market by Drug Product 35

4.1 Market Overview by Drug Product 35

4.2 Modern Human Insulin 37

4.2.1 Modern Human Insulin by Type 39

4.2.2 Modern Human Insulin by Brand 42

4.3 Traditional Human Insulin 49

4.3.1 Traditional Human Insulin by Type 51

4.3.2 Traditional Human Insulin by Brand 54

5 Segmentation of Asia-Pacific Human Insulin Delivery Devices Market by Device Product 57

5.1 Market Overview by Product 57

5.2 Syringes 59

5.3 Pens 60

5.4 Pumps 61

5.5 Other Devices 63

6 Segmentation of Asia-Pacific Market by Application 64

6.1 Market Overview by Application 64

6.2 Type 1 Diabetes 66

6.3 Type 2 Diabetes 67

6.4 Gestational Diabetes and Prediabetes 68

7 Segmentation of Asia-Pacific Market by Distribution Channel 69

7.1 Market Overview by Distribution Channel 69

7.2 Hospital Pharmacies 71

7.3 Retail Pharmacies 72

7.4 Online Pharmacies 73

8 Asia-Pacific Market 2019-2026 by Country 74

8.1 Overview of Asia-Pacific Market 74

8.2 Japan 77

8.3 China 80

8.4 Australia 82

8.5 India 84

8.6 South Korea 86

8.7 Rest of APAC Region 88

9 Competitive Landscape 90

9.1 Overview of Key Vendors 90

9.2 New Product Launch, Partnership, Investment, and M&A 94

9.3 Company Profiles 96

Astra Zeneca PLC 96

Biocon 98

Eli Lilly 99

Exir 100

Julphar 101

Novo Nordisk AS 102

Pfizer 103

Sanofi Aventis 104

Sedico 105

Wockhardt 106

10 Investing in Asia-Pacific Market: Risk Assessment and Management 107

10.1 Risk Evaluation of Asia-Pacific Market 107

10.2 Critical Success Factors (CSFs) 110

Related Reports and Products 113


List Of Figure

Figure 1. Research Method Flow Chart 10

Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 13

Figure 3. Asia-Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2026 15

Figure 4. Asia-Pacific Human Insulin Market, 2019-2026, USD mn 17

Figure 5. Primary Drivers and Impact Factors of Asia-Pacific Human Insulin Market 18

Figure 6. Primary Restraints and Impact Factors of Asia-Pacific Human Insulin Market 21

Figure 7. Porter's Fiver Forces Analysis of Asia-Pacific Human Insulin Market 27

Figure 8. Breakdown of Asia-Pacific Human Insulin Market by Product Type, 2019-2026, % of Revenue 31

Figure 9. Contribution to Asia-Pacific 2020-2026 Cumulative Revenue by Product Type, Value (USD mn) and Share (%) 32

Figure 10. Asia-Pacific Human Insulin Market: Human Insulin Drugs, 2019-2026, USD mn 33

Figure 11. Asia-Pacific Human Insulin Market: Human Insulin Delivery Devices, 2019-2026, USD mn 34

Figure 12. Breakdown of Asia-Pacific Human Insulin Drugs Market by Product, 2019-2026, % of Revenue 35

Figure 13. Contribution to Asia-Pacific Human Insulin Drugs Cumulative Revenue by Product, 2020-2026, Value (USD mn) and Share (%) 36

Figure 14. Asia-Pacific Human Insulin Market: Modern Human Insulin, 2019-2026, USD mn 37

Figure 15. Asia-Pacific Modern Human Insulin Market: Long-acting, 2019-2026, USD mn 39

Figure 16. Asia-Pacific Modern Human Insulin Market: Rapid- acting, 2019-2026, USD mn 40

Figure 17. Asia-Pacific Modern Human Insulin Market: Premixed, 2019-2026, USD mn 41

Figure 18. Asia-Pacific Modern Human Insulin Market: Lantus, 2019-2026, USD mn 42

Figure 19. Asia-Pacific Modern Human Insulin Market: Apidra, 2019-2026, USD mn 43

Figure 20. Asia-Pacific Modern Human Insulin Market: Levemir, 2019-2026, USD mn 44

Figure 21. Asia-Pacific Modern Human Insulin Market: NovoRapid/ NovoLog, 2019-2026, USD mn 45

Figure 22. Asia-Pacific Modern Human Insulin Market: Novomix, 2019-2026, USD mn 46

Figure 23. Asia-Pacific Modern Human Insulin Market: Humalog, 2019-2026, USD mn 47

Figure 24. Asia-Pacific Modern Human Insulin Market: Other Brands, 2019-2026, USD mn 48

Figure 25. Asia-Pacific Human Insulin Market: Traditional Human Insulin, 2019-2026, USD mn 49

Figure 26. Asia-Pacific Traditional Human Insulin Market: Short-acting, 2019-2026, USD mn 51

Figure 27. Asia-Pacific Traditional Human Insulin Market: Intermediate & Rapid-acting, 2019-2026, USD mn 52

Figure 28. Asia-Pacific Traditional Human Insulin Market: Premixed, 2019-2026, USD mn 53

Figure 29. Asia-Pacific Traditional Human Insulin Market: Humulin, 2019-2026, USD mn 54

Figure 30. Asia-Pacific Traditional Human Insulin Market: Insuman, 2019-2026, USD mn 55

Figure 31. Asia-Pacific Traditional Human Insulin Market: Novolin/Actrapid/Insulatard, 2019-2026, USD mn 56

Figure 32. Breakdown of Asia-Pacific Human Insulin Delivery Devices Market by Product, 2019-2026, % of Revenue 57

Figure 33. Contribution to Asia-Pacific Human Insulin Delivery Devices Cumulative Revenue by Product, 2020-2026, Value (USD mn) and Share (%) 58

Figure 34. Asia-Pacific Human Insulin Delivery Devices Market: Syringes, 2019-2026, USD mn 59

Figure 35. Asia-Pacific Human Insulin Delivery Devices Market: Pens, 2019-2026, USD mn 60

Figure 36. Asia-Pacific Human Insulin Delivery Devices Market: Pumps, 2019-2026, USD mn 61

Figure 37. Asia-Pacific Human Insulin Delivery Devices Market: Other Devices, 2019-2026, USD mn 63

Figure 38. Breakdown of Asia-Pacific Human Insulin Market by Application, 2019-2026, % of Revenue 64

Figure 39. Contribution to Asia-Pacific 2020-2026 Cumulative Revenue by Application, Value (USD mn) and Share (%) 65

Figure 40. Asia-Pacific Human Insulin Market: Type 1 Diabetes, 2019-2026, USD mn 66

Figure 41. Asia-Pacific Human Insulin Market: Type 2 Diabetes, 2019-2026, USD mn 67

Figure 42. Asia-Pacific Human Insulin Market: Gestational Diabetes and Prediabetes, 2019-2026, USD mn 68

Figure 43. Breakdown of Asia-Pacific Human Insulin Market by Distribution Channel, 2019-2026, % of Revenue 69

Figure 44. Contribution to Asia-Pacific 2020-2026 Cumulative Revenue by Distribution Channel, Value (USD mn) and Share (%) 70

Figure 45. Asia-Pacific Human Insulin Market: Hospital Pharmacies, 2019-2026, USD mn 71

Figure 46. Asia-Pacific Human Insulin Market: Retail Pharmacies, 2019-2026, USD mn 72

Figure 47. Asia-Pacific Human Insulin Market: Online Pharmacies, 2019-2026, USD mn 73

Figure 48. Breakdown of APAC Human Insulin Market by Country, 2019 and 2026, % of Revenue 75

Figure 49. Contribution to APAC 2020-2026 Cumulative Revenue by Country, Value (USD mn) and Share (%) 76

Figure 50. Human Insulin Market in Japan, 2019-2026, USD mn 78

Figure 51. Human Insulin Market in China, 2019-2026, USD mn 80

Figure 52. Human Insulin Market in Australia, 2019-2026, USD mn 82

Figure 53. Human Insulin Market in India, 2019-2026, USD mn 84

Figure 54. Human Insulin Market in South Korea, 2019-2026, USD mn 86

Figure 55. Human Insulin Market in Rest of APAC, 2019-2026, USD mn 88

Figure 56. Growth Stage of Asia-Pacific Human Insulin Industry over the Forecast Period 90


List Of Table

Table 1. Snapshot of Asia-Pacific Human Insulin Market, 2019-2026 16

Table 2. Main Product Trends and Market Opportunities in Asia-Pacific Human Insulin Market 24

Table 3. Asia-Pacific Human Insulin Market by Product Type, 2019-2026, USD mn 31

Table 4. Asia-Pacific Human Insulin Drugs Market by Product, 2019-2026, USD mn 35

Table 5. Asia-Pacific Human Insulin Drugs Market: Modern Human Insulin by Type, 2019-2026, USD mn 38

Table 6. Asia-Pacific Human Insulin Drugs Market: Modern Human Insulin by Brand, 2019-2026, USD mn 38

Table 7. Asia-Pacific Human Insulin Drugs Market: Traditional Human Insulin by Type, 2019-2026, USD mn 50

Table 8. Asia-Pacific Human Insulin Drugs Market: Traditional Human Insulin by Brand, 2019-2026, USD mn 50

Table 9. Asia-Pacific Human Insulin Delivery Devices Market by Product, 2019-2026, USD mn 57

Table 10. Asia-Pacific Human Insulin Delivery Devices Market: Pens by Product, 2019-2026, USD mn 60

Table 11. Asia-Pacific Human Insulin Market by Application, 2019-2026, USD mn 64

Table 12. Asia-Pacific Human Insulin Market by Distribution Channel, 2019-2026, USD mn 69

Table 13. APAC Human Insulin Market by Country, 2019-2026, USD mn 75

Table 14. Japan Human Insulin Market by Product Type, 2019-2026, USD mn 79

Table 15. Japan Human Insulin Market by Application, 2019-2026, USD mn 79

Table 16. Japan Human Insulin Market by Distribution Channel, 2019-2026, USD mn 79

Table 17. China Human Insulin Market by Product Type, 2019-2026, USD mn 81

Table 18. China Human Insulin Market by Application, 2019-2026, USD mn 81

Table 19. China Human Insulin Market by Distribution Channel, 2019-2026, USD mn 81

Table 20. Australia Human Insulin Market by Product Type, 2019-2026, USD mn 83

Table 21. Australia Human Insulin Market by Application, 2019-2026, USD mn 83

Table 22. Australia Human Insulin Market by Distribution Channel, 2019-2026, USD mn 83

Table 23. India Human Insulin Market by Product Type, 2019-2026, USD mn 85

Table 24. India Human Insulin Market by Application, 2019-2026, USD mn 85

Table 25. India Human Insulin Market by Distribution Channel, 2019-2026, USD mn 85

Table 26. South Korea Human Insulin Market by Product Type, 2019-2026, USD mn 87

Table 27. South Korea Human Insulin Market by Application, 2019-2026, USD mn 87

Table 28. South Korea Human Insulin Market by Distribution Channel, 2019-2026, USD mn 87

Table 29. Human Insulin Market in Rest of APAC by Country, 2019-2026, USD mn 89

Table 30. Asia-Pacific Human Insulin Market by Key Vendor, 2019, USD mn 92

Table 31. Astra Zeneca PLC: Company Snapshot 96

Table 32. Astra Zeneca PLC: Business Segmentation 96

Table 33. Astra Zeneca PLC: Product Portfolio 97

Table 34. Astra Zeneca PLC: Revenue, 2016-2018, USD mn 97

Table 35. Astra Zeneca PLC: Recent Developments 97

Table 36. Risk Evaluation for Investing in Asia-Pacific Market, 2019-2026 108

Table 37. Critical Success Factors and Key Takeaways 111

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Astra Zeneca PLC

Biocon

Eli Lilly

Exir

Julphar

Novo Nordisk AS

Pfizer

Sanofi Aventis

Sedico

Wockhardt

Company Profile

Company Profile Title

Asia Pacific human insulin market will grow by 9.74% annually over forecast years with a total addressable market cap of USD 66.02 billion for 2020-2026.

Highlighted with 37 tables and 56 figures, this 113-page report Asia Pacific Human Insulin Market 2020-2026 by Product Type (Drugs, Delivery Devices), Application (Type 1 Diabetes, Type 2 Diabetes, Others), Distribution Channel, and Country: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire Asia Pacific human insulin market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. In this report 2019 is the base year for market analysis, with estimates and forecast covering 2020-2026. (Please Note: The report will be updated before delivery to make sure that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

o Market Structure

o Growth Drivers

o Restraints and Challenges

o Emerging Product Trends & Market Opportunities

o Porter's Fiver Forces

The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view. The balanced (most likely) projection is used to quantify Asia Pacific human insulin market in every aspect of the classification from perspectives of Product Type, Application, Distribution Channel, and Country.

Based on product type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.

o Human Insulin Drugs

o Human Insulin Delivery Devices

Based on product, the Asia Pacific Human Insulin Drugs market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.

o Modern Human Insulin (further segmented into Long-acting, Rapid- acting, Premixed by type; further segmented into Lantus, Apidra, Levemir, NovoRapid/ NovoLog, Novomix, Humalog, Others by brand)

o Traditional Human Insulin (further segmented into Short-acting, Intermediate & Rapid-acting, Premixed by type; further segmented into Humulin, Insuman, Novolin/Actrapid/Insulatard by brand)

Based on product, the Asia Pacific Human Insulin Delivery Devices market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.

o Syringes

o Pens (further segmented into Disposable, Reusable, Pen needles)

o Pumps

o Others

Based on application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.

o Type 1 Diabetes

o Type 2 Diabetes

o Gestational Diabetes and Prediabetes

Based on distribution channel, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.

o Hospital Pharmacies

o Retail Pharmacies

o Online Pharmacies

Geographically, the following national/local markets are fully investigated:

o Japan

o China

o South Korea

o Australia

o India

o Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)

For each of the aforementioned countries, market analysis and revenue data are available for 2019-2026. The breakdown of major national markets by Product Type, Application, and Distribution Channel over the study years (2019-2026) is included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in Asia Pacific human insulin market are assayed quantitatively and qualitatively through GMD's Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players:

Astra Zeneca PLC

Biocon

Eli Lilly

Exir

Julphar

Novo Nordisk AS

Pfizer

Sanofi Aventis

Sedico

Wockhardt

(Please Note: The report will be updated before delivery to make sure that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

READ MORE

Scope

1 Introduction 7

1.1 Industry Definition and Research Scope 7

1.1.1 Industry Definition 7

1.1.2 Research Scope 8

1.2 Research Methodology 10

1.2.1 Overview of Market Research Methodology 10

1.2.2 Market Assumption 11

1.2.3 Secondary Data 11

1.2.4 Primary Data 11

1.2.5 Data Filtration and Model Design 12

1.2.6 Market Size/Share Estimation 13

1.2.7 Research Limitations 14

1.3 Executive Summary 15

2 Market Overview and Dynamics 17

2.1 Market Size and Forecast 17

2.2 Major Growth Drivers 18

2.3 Market Restraints and Challenges 21

2.4 Emerging Opportunities and Market Trends 24

2.5 Porter's Fiver Forces Analysis 27

3 Segmentation of Asia-Pacific Market by Product Type 31

3.1 Market Overview by Product Type 31

3.2 Human Insulin Drugs 33

3.3 Human Insulin Delivery Devices 34

4 Segmentation of Asia-Pacific Human Insulin Drugs Market by Drug Product 35

4.1 Market Overview by Drug Product 35

4.2 Modern Human Insulin 37

4.2.1 Modern Human Insulin by Type 39

4.2.2 Modern Human Insulin by Brand 42

4.3 Traditional Human Insulin 49

4.3.1 Traditional Human Insulin by Type 51

4.3.2 Traditional Human Insulin by Brand 54

5 Segmentation of Asia-Pacific Human Insulin Delivery Devices Market by Device Product 57

5.1 Market Overview by Product 57

5.2 Syringes 59

5.3 Pens 60

5.4 Pumps 61

5.5 Other Devices 63

6 Segmentation of Asia-Pacific Market by Application 64

6.1 Market Overview by Application 64

6.2 Type 1 Diabetes 66

6.3 Type 2 Diabetes 67

6.4 Gestational Diabetes and Prediabetes 68

7 Segmentation of Asia-Pacific Market by Distribution Channel 69

7.1 Market Overview by Distribution Channel 69

7.2 Hospital Pharmacies 71

7.3 Retail Pharmacies 72

7.4 Online Pharmacies 73

8 Asia-Pacific Market 2019-2026 by Country 74

8.1 Overview of Asia-Pacific Market 74

8.2 Japan 77

8.3 China 80

8.4 Australia 82

8.5 India 84

8.6 South Korea 86

8.7 Rest of APAC Region 88

9 Competitive Landscape 90

9.1 Overview of Key Vendors 90

9.2 New Product Launch, Partnership, Investment, and M&A 94

9.3 Company Profiles 96

Astra Zeneca PLC 96

Biocon 98

Eli Lilly 99

Exir 100

Julphar 101

Novo Nordisk AS 102

Pfizer 103

Sanofi Aventis 104

Sedico 105

Wockhardt 106

10 Investing in Asia-Pacific Market: Risk Assessment and Management 107

10.1 Risk Evaluation of Asia-Pacific Market 107

10.2 Critical Success Factors (CSFs) 110

Related Reports and Products 113


List Of Figure

Figure 1. Research Method Flow Chart 10

Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 13

Figure 3. Asia-Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2026 15

Figure 4. Asia-Pacific Human Insulin Market, 2019-2026, USD mn 17

Figure 5. Primary Drivers and Impact Factors of Asia-Pacific Human Insulin Market 18

Figure 6. Primary Restraints and Impact Factors of Asia-Pacific Human Insulin Market 21

Figure 7. Porter's Fiver Forces Analysis of Asia-Pacific Human Insulin Market 27

Figure 8. Breakdown of Asia-Pacific Human Insulin Market by Product Type, 2019-2026, % of Revenue 31

Figure 9. Contribution to Asia-Pacific 2020-2026 Cumulative Revenue by Product Type, Value (USD mn) and Share (%) 32

Figure 10. Asia-Pacific Human Insulin Market: Human Insulin Drugs, 2019-2026, USD mn 33

Figure 11. Asia-Pacific Human Insulin Market: Human Insulin Delivery Devices, 2019-2026, USD mn 34

Figure 12. Breakdown of Asia-Pacific Human Insulin Drugs Market by Product, 2019-2026, % of Revenue 35

Figure 13. Contribution to Asia-Pacific Human Insulin Drugs Cumulative Revenue by Product, 2020-2026, Value (USD mn) and Share (%) 36

Figure 14. Asia-Pacific Human Insulin Market: Modern Human Insulin, 2019-2026, USD mn 37

Figure 15. Asia-Pacific Modern Human Insulin Market: Long-acting, 2019-2026, USD mn 39

Figure 16. Asia-Pacific Modern Human Insulin Market: Rapid- acting, 2019-2026, USD mn 40

Figure 17. Asia-Pacific Modern Human Insulin Market: Premixed, 2019-2026, USD mn 41

Figure 18. Asia-Pacific Modern Human Insulin Market: Lantus, 2019-2026, USD mn 42

Figure 19. Asia-Pacific Modern Human Insulin Market: Apidra, 2019-2026, USD mn 43

Figure 20. Asia-Pacific Modern Human Insulin Market: Levemir, 2019-2026, USD mn 44

Figure 21. Asia-Pacific Modern Human Insulin Market: NovoRapid/ NovoLog, 2019-2026, USD mn 45

Figure 22. Asia-Pacific Modern Human Insulin Market: Novomix, 2019-2026, USD mn 46

Figure 23. Asia-Pacific Modern Human Insulin Market: Humalog, 2019-2026, USD mn 47

Figure 24. Asia-Pacific Modern Human Insulin Market: Other Brands, 2019-2026, USD mn 48

Figure 25. Asia-Pacific Human Insulin Market: Traditional Human Insulin, 2019-2026, USD mn 49

Figure 26. Asia-Pacific Traditional Human Insulin Market: Short-acting, 2019-2026, USD mn 51

Figure 27. Asia-Pacific Traditional Human Insulin Market: Intermediate & Rapid-acting, 2019-2026, USD mn 52

Figure 28. Asia-Pacific Traditional Human Insulin Market: Premixed, 2019-2026, USD mn 53

Figure 29. Asia-Pacific Traditional Human Insulin Market: Humulin, 2019-2026, USD mn 54

Figure 30. Asia-Pacific Traditional Human Insulin Market: Insuman, 2019-2026, USD mn 55

Figure 31. Asia-Pacific Traditional Human Insulin Market: Novolin/Actrapid/Insulatard, 2019-2026, USD mn 56

Figure 32. Breakdown of Asia-Pacific Human Insulin Delivery Devices Market by Product, 2019-2026, % of Revenue 57

Figure 33. Contribution to Asia-Pacific Human Insulin Delivery Devices Cumulative Revenue by Product, 2020-2026, Value (USD mn) and Share (%) 58

Figure 34. Asia-Pacific Human Insulin Delivery Devices Market: Syringes, 2019-2026, USD mn 59

Figure 35. Asia-Pacific Human Insulin Delivery Devices Market: Pens, 2019-2026, USD mn 60

Figure 36. Asia-Pacific Human Insulin Delivery Devices Market: Pumps, 2019-2026, USD mn 61

Figure 37. Asia-Pacific Human Insulin Delivery Devices Market: Other Devices, 2019-2026, USD mn 63

Figure 38. Breakdown of Asia-Pacific Human Insulin Market by Application, 2019-2026, % of Revenue 64

Figure 39. Contribution to Asia-Pacific 2020-2026 Cumulative Revenue by Application, Value (USD mn) and Share (%) 65

Figure 40. Asia-Pacific Human Insulin Market: Type 1 Diabetes, 2019-2026, USD mn 66

Figure 41. Asia-Pacific Human Insulin Market: Type 2 Diabetes, 2019-2026, USD mn 67

Figure 42. Asia-Pacific Human Insulin Market: Gestational Diabetes and Prediabetes, 2019-2026, USD mn 68

Figure 43. Breakdown of Asia-Pacific Human Insulin Market by Distribution Channel, 2019-2026, % of Revenue 69

Figure 44. Contribution to Asia-Pacific 2020-2026 Cumulative Revenue by Distribution Channel, Value (USD mn) and Share (%) 70

Figure 45. Asia-Pacific Human Insulin Market: Hospital Pharmacies, 2019-2026, USD mn 71

Figure 46. Asia-Pacific Human Insulin Market: Retail Pharmacies, 2019-2026, USD mn 72

Figure 47. Asia-Pacific Human Insulin Market: Online Pharmacies, 2019-2026, USD mn 73

Figure 48. Breakdown of APAC Human Insulin Market by Country, 2019 and 2026, % of Revenue 75

Figure 49. Contribution to APAC 2020-2026 Cumulative Revenue by Country, Value (USD mn) and Share (%) 76

Figure 50. Human Insulin Market in Japan, 2019-2026, USD mn 78

Figure 51. Human Insulin Market in China, 2019-2026, USD mn 80

Figure 52. Human Insulin Market in Australia, 2019-2026, USD mn 82

Figure 53. Human Insulin Market in India, 2019-2026, USD mn 84

Figure 54. Human Insulin Market in South Korea, 2019-2026, USD mn 86

Figure 55. Human Insulin Market in Rest of APAC, 2019-2026, USD mn 88

Figure 56. Growth Stage of Asia-Pacific Human Insulin Industry over the Forecast Period 90


List Of Table

Table 1. Snapshot of Asia-Pacific Human Insulin Market, 2019-2026 16

Table 2. Main Product Trends and Market Opportunities in Asia-Pacific Human Insulin Market 24

Table 3. Asia-Pacific Human Insulin Market by Product Type, 2019-2026, USD mn 31

Table 4. Asia-Pacific Human Insulin Drugs Market by Product, 2019-2026, USD mn 35

Table 5. Asia-Pacific Human Insulin Drugs Market: Modern Human Insulin by Type, 2019-2026, USD mn 38

Table 6. Asia-Pacific Human Insulin Drugs Market: Modern Human Insulin by Brand, 2019-2026, USD mn 38

Table 7. Asia-Pacific Human Insulin Drugs Market: Traditional Human Insulin by Type, 2019-2026, USD mn 50

Table 8. Asia-Pacific Human Insulin Drugs Market: Traditional Human Insulin by Brand, 2019-2026, USD mn 50

Table 9. Asia-Pacific Human Insulin Delivery Devices Market by Product, 2019-2026, USD mn 57

Table 10. Asia-Pacific Human Insulin Delivery Devices Market: Pens by Product, 2019-2026, USD mn 60

Table 11. Asia-Pacific Human Insulin Market by Application, 2019-2026, USD mn 64

Table 12. Asia-Pacific Human Insulin Market by Distribution Channel, 2019-2026, USD mn 69

Table 13. APAC Human Insulin Market by Country, 2019-2026, USD mn 75

Table 14. Japan Human Insulin Market by Product Type, 2019-2026, USD mn 79

Table 15. Japan Human Insulin Market by Application, 2019-2026, USD mn 79

Table 16. Japan Human Insulin Market by Distribution Channel, 2019-2026, USD mn 79

Table 17. China Human Insulin Market by Product Type, 2019-2026, USD mn 81

Table 18. China Human Insulin Market by Application, 2019-2026, USD mn 81

Table 19. China Human Insulin Market by Distribution Channel, 2019-2026, USD mn 81

Table 20. Australia Human Insulin Market by Product Type, 2019-2026, USD mn 83

Table 21. Australia Human Insulin Market by Application, 2019-2026, USD mn 83

Table 22. Australia Human Insulin Market by Distribution Channel, 2019-2026, USD mn 83

Table 23. India Human Insulin Market by Product Type, 2019-2026, USD mn 85

Table 24. India Human Insulin Market by Application, 2019-2026, USD mn 85

Table 25. India Human Insulin Market by Distribution Channel, 2019-2026, USD mn 85

Table 26. South Korea Human Insulin Market by Product Type, 2019-2026, USD mn 87

Table 27. South Korea Human Insulin Market by Application, 2019-2026, USD mn 87

Table 28. South Korea Human Insulin Market by Distribution Channel, 2019-2026, USD mn 87

Table 29. Human Insulin Market in Rest of APAC by Country, 2019-2026, USD mn 89

Table 30. Asia-Pacific Human Insulin Market by Key Vendor, 2019, USD mn 92

Table 31. Astra Zeneca PLC: Company Snapshot 96

Table 32. Astra Zeneca PLC: Business Segmentation 96

Table 33. Astra Zeneca PLC: Product Portfolio 97

Table 34. Astra Zeneca PLC: Revenue, 2016-2018, USD mn 97

Table 35. Astra Zeneca PLC: Recent Developments 97

Table 36. Risk Evaluation for Investing in Asia-Pacific Market, 2019-2026 108

Table 37. Critical Success Factors and Key Takeaways 111

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Astra Zeneca PLC

Biocon

Eli Lilly

Exir

Julphar

Novo Nordisk AS

Pfizer

Sanofi Aventis

Sedico

Wockhardt